This is a cached page for the URL (http://www.biotechniques.com/default.asp?page=protocol&subsection=article_display&id=112359). To see the most recent version of this page, please click here.
Protocol Online is not affiliated with the authors of this page nor responsible for its content.
About Cache
Producing siRNA for in vivo applications | Protocol Guide | BioTechniques®
BioTechniques(R) - The International Journal For Life Science Methods
 
Advanced search
www.biotechniques.com
Subscribe to BioTechniques | 
 | Print This Page
Current Issue:
January 2009
January 2009
About the cover
Home » Protocol Guide » Archive » 2007 Guide » Integrated DNA Technologies (p 77)
BioTechniques®  Protocol Guide 2007
Published December 2006: p 77

RNAi

siRNA

Producing siRNA for in vivo applications
Integrated DNA Technologies

Background

SiRNA is widely used for analyzing gene function and target validation in vitro and in recent years has been successfully extended to in vivo research. Integrated DNA Technologies (IDT) synthesizes siRNAs for both in vitro and in vivo applications. Researchers planning in vivo work should be aware that potentially toxic substances can be introduced during oligonucleotide synthesis and purification (HPLC) processes, which must be removed to prevent erroneous results and/or the death of laboratory animals.

Elements of proper manufacturing protocols for siRNA intended for in vivo use that help eliminate toxic substances include:

• Adding trace EDTA in HPLC buffers to remove heavy metal cations.

• Using only biocompatible buffers and salts such as sodium phosphate and sodium chloride for HPLC.

• Maintaining an endotoxin-free environment.

The Endotoxin Problem

The classic endotoxin is lipopolysaccharide (LPS), a natural product present in the outer membrane of the cell wall of Gram negative bacteria. Toxic LPS is liberated whenever these bacteria die. If present as a contaminant in reagents used in vivo, it can cause severe inflammatory responses and/or death of the animals. In mammals LPS binds to serum proteins and interacts with various receptors on monocytes, macrophages, and endothelial cells. This eventually triggers cytokine production, complement activation, and coagulation cascades.

The majority of endotoxins are liberated when bacteria are lysed. These molecules are particularly difficult to degrade, being composed of a complicated sugar chain and lipid A. Interestingly, the major source of endotoxin contamination in manufacturing is water—in particular, sterile water.

The following guidelines help reduce the chance of LPS contamination of siRNAs intended for in vivo use:

• Follow standardized laboratory protocols for all stages of production.

• Work in a clean environment.

• Wear disposable gloves and other barriers.

• Maintain and clean the water purification system routinely.

• Autoclave all glassware at 180°C.

• Use high purity molecular biology grade salts for buffer preparation.

• Replace sterile water and buffers frequently to minimize potential for bacterial colonization.

• Use disposable sterile plasticware when possible.

• Use air filters to maintain an aseptic environment during ultrafiltration.

• Sterile filter the annealed duplex prior to lyophilization; release vacuum using an in-line sterile air filter to prevent bacterial ingress.

• Verify absence of endotoxins by QC testing the final product. We employ an external laboratory with a validated Limulus amebocyte lysate (LAL) test. "Pass" level should not exceed 2 EU/mg.

Using these protocols, detectable endotoxin levels for IDT's "in vivo clean siRNAs" are usually in the range of 0.01 to 0.1 EU/mg. This high level of care is needed to produce high quality reagents that are suitable for critical in vivo research and preclinical studies.


Read the complete Protocol
Log-in for full article

Visit the Integrated DNA Technologies Web site

Return to table of contents for the 2007 Protocol Guide

2007 Protocol Guide
December 2006
Contact Integrated DNA Technologies:
Please login or fill out the form below to request information from Integrated DNA Technologies.

* - Denotes required field

* First name:
* Last name:
* Company:
* Phone:
* Email:

» Visit their Web site

Login for full article
Order a reprint of this article.
Search BioTechniques.com:   Advanced Search | Archive | Most Popular
About us | Privacy policy | Terms and Conditions | Informa Life Sciences Group
© 1983-2009 BioTechniques
212-520-2777 · Contact Us